CMN Weekly (7 June 2024) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jun. 7, 2024

Top picks

  • Dengue lacks approved antivirals, but systemic delivery of mRNA-encoded Cas13a and guide RNAs in lipid nanoparticles shows promise. Guides against DENV2 and DENV3 were effective in vitro. A single dose of this formulation, given one-day post-infection, increased survival and reduced viral titres in mice. RNA sequencing revealed no off-target effects, highlighting mRNA-encoded Cas13's potential as a pan-DENV treatment.
  • OliTag-seq, an in-cellulo assay, improves CRISPR-Cas9 off-target detection with stable oligonucleotide tagging and triple-priming amplification. It surpasses traditional methods in coverage and accuracy, especially in iPSCs. Enhanced by prolonged Cas9 expression and HDAC inhibitor treatments, OliTag-seq offers high sensitivity and practical application, making it essential for precise genome editing assessment in research and clinical environments.

Research

Industry

CRISPR screens

Reviews

Webinars

News from CRISPR Medicine News

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN WeeklyHashtagERS GenomicsHashtagVerve Therapeutics, Inc.

News: CMN Weekly (7 June 2024) - Your Weekly CRISPR Medicine News
News: CMN Weekly (7 June 2024) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine